ClinicalTrials.gg

Program

daraxonrasib

Also written as “RMC-6236”, “Daraxonrasib” and “Daraxonrasib (Cohort B1 only)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Pancreatic Neoplasms · Colorectal Neoplasms, led by Revolution Medicines.

Furthest: phase 3, since Sep 20, 202410 company-led studies, 10 open or runningNext primary completion: May 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Revolution Medicines1010 open or runningphase 3since Sep 20, 2024May 13, 2022May 31, 2027phase 2 · NCT05379985

Also a collaborator on its studies: summit-therapeutics.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 13, 2022First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05379985 · 754 planned · United States
  2. Nov 7, 20232 phase 2 studies in Carcinoma, Non-Small-Cell LungNCT06128551, NCT06162221
  3. May 20, 2024Phase 2 study in Colorectal NeoplasmsNCT06445062 · 1,130 planned · United States
  4. Sep 20, 2024Phase 3 study in Pancreatic NeoplasmsNCT06625320 · 500 enrolled · United States, France, Germany and more
  5. Mar 10, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06881784 · 590 planned · United States, Australia, Belgium and more
  6. Nov 13, 2025Phase 3 study in Pancreatic NeoplasmsNCT07252232 · 500 planned · United States, Canada, France and more
  7. Feb 2, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07397338 · 370 planned · United States
  8. Mar 10, 2026Phase 3 study in Pancreatic NeoplasmsNCT07491445 · 900 planned · United States, Australia, Austria and more
  9. Sep 1, 2026Phase 3 study in Pancreatic NeoplasmsNCT07805954 · 400 planned · United States

Ahead

  1. May 31, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT05379985
  2. Jun 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06162221
  3. Dec 1, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06881784
  4. Apr 2028Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07491445

TargetBeta

“An orally bioavailable inhibitor of the active, guanosine triphosphate (GTP)-bound form of both wild type and mutant variants of the RAS isoforms, including HRAS, NRAS and KRAS, ”NCIt, by rule

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07805954Pancreatic Neoplasms · United States3RecruitingMar 2029400
NCT07491445Pancreatic Neoplasms · United States, Australia, Austria and more3RecruitingApr 2028900
NCT07397338Carcinoma, Non-Small-Cell Lung · United States2RecruitingMay 2029370
NCT07252232Pancreatic Neoplasms · United States, Canada, France and more3RecruitingMay 10, 2029500
NCT06881784Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more3RecruitingDec 1, 2027590
NCT06625320Pancreatic Neoplasms · United States, France, Germany and more3Active, not recruitingJun 2026500
NCT06445062Colorectal Neoplasms · United States2RecruitingSep 30, 20281,130
NCT06162221Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more2RecruitingJun 2027616
NCT06128551Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more2RecruitingDec 2028534
NCT05379985Carcinoma, Non-Small-Cell Lung · United States2RecruitingMay 31, 2027754

How it is read

Names in the registry

  • “daraxonrasib”, 4 entries
  • “RMC-6236”, 4 entries
  • “Daraxonrasib”, 2 entries
  • “Daraxonrasib (Cohort B1 only)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.